https://peptidescanner.com/whats-new/Follow selected PeptideScanner profile, review, study, official-source-note and source-record additions with their source, review and site dates kept separate.en-ushttps://peptidescanner.com/studies/#study-nct01394952peptidescanner:whats-new:study:NCT01394952:v2Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke. Site addition: 2026-09-20. Source date: Registry source date 2019-10-08. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The reported median follow-up was 5.4 years. The composite result does not establish benefit for every component, and all-cause mortality did not differ significantly. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01394952); PubMed PMID 31189511 (https://pubmed.ncbi.nlm.nih.gov/31189511/)2026-09-20Study context updateddulaglutidehttps://peptidescanner.com/studies/#study-nct03323749peptidescanner:whats-new:study:NCT03323749:v2Change in six-minute walking distance and symptom-assessment total fatigue score at week 24. Site addition: 2026-09-20. Source date: Registry source date 2022-01-24. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: Neither primary endpoint was met. Findings in primary mitochondrial myopathy should not be substituted for evidence in Barth syndrome. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03323749); PubMed PMID 37268435 (https://pubmed.ncbi.nlm.nih.gov/37268435/)2026-09-20Study context updatedelamipretidehttps://peptidescanner.com/studies/#study-nct03548935peptidescanner:whats-new:study:NCT03548935:v2Percentage weight change and the proportion losing at least 5% of baseline weight at week 68. Site addition: 2026-09-20. Source date: Registry source date 2021-11-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The main report describes treatment-period outcomes in adults without diabetes. A separately appraised extension below follows selected participants after medication and structured lifestyle support stopped; it does not provide a randomized comparison of continuing versus stopping treatment. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03548935); PubMed PMID 33567185 (https://pubmed.ncbi.nlm.nih.gov/33567185/)2026-09-20Study context updatedsemaglutidehttps://peptidescanner.com/studies/#study-nct03574597peptidescanner:whats-new:study:NCT03574597:v2Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke; the registry observation window extended to 240 weeks. Site addition: 2026-09-20. Source date: Registry source date 2024-08-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report gives a mean follow-up of 39.8 months. That observed follow-up differs from the maximum registry observation window. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03574597); PubMed PMID 37952131 (https://pubmed.ncbi.nlm.nih.gov/37952131/)2026-09-20Study context updatedsemaglutidehttps://peptidescanner.com/studies/#study-nct04026113peptidescanner:whats-new:study:NCT04026113:v2For functional constipation, change in weekly spontaneous bowel-movement frequency over 12 weeks; the registry has a separate primary endpoint for its IBS-C cohort. Site addition: 2026-09-20. Source date: Registry source date 2024-11-26. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry covers 438 participants across two conditions. This report concerns 330 randomized children with functional constipation, of whom 328 received treatment. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04026113); PubMed PMID 38211604 (https://pubmed.ncbi.nlm.nih.gov/38211604/)2026-09-20Study context updatedlinaclotidehttps://peptidescanner.com/studies/#study-nct04184622peptidescanner:whats-new:study:NCT04184622:v2Percentage weight change and the proportion losing at least 5% of baseline weight at week 72. Site addition: 2026-09-20. Source date: Registry source date 2025-07-24. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The main report concerns adults without diabetes and its 72-week weight endpoints. Separately appraised publications below examine patient-reported outcomes and exploratory physical-function subgroups from the same trial. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04184622); PubMed PMID 35658024 (https://pubmed.ncbi.nlm.nih.gov/35658024/)2026-09-20Study context updatedtirzepatidehttps://peptidescanner.com/studies/#study-nct04881760peptidescanner:whats-new:study:NCT04881760:v2Percentage change in body weight at week 24. Site addition: 2026-09-20. Source date: Registry source date 2023-09-13. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The often-cited 48-week weight results are secondary outcomes; the primary endpoint was measured at week 24. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04881760); PubMed PMID 37366315 (https://pubmed.ncbi.nlm.nih.gov/37366315/)2026-09-20Study context updatedretatrutidehttps://peptidescanner.com/studies/#study-nct00123253peptidescanner:whats-new:study:NCT00123253:v1Visceral adipose tissue; the retrieved primary-outcome field does not specify a time frame. Site addition: 2026-09-20. Source date: Registry source date 2013-11-27. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The publication reports a 26-week comparison using imaging of abdominal fat. That result is not a cardiovascular-outcome trial or a general-obesity result. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00123253); PubMed PMID 18057338 (https://pubmed.ncbi.nlm.nih.gov/18057338/)2026-09-20Study context addedtesamorelinhttps://peptidescanner.com/studies/#study-nct00353496peptidescanner:whats-new:study:NCT00353496:v1Time to tumor progression or death, with assessments scheduled through week 96. Site addition: 2026-09-20. Source date: Registry source date 2025-03-05. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report describes 204 randomized participants; the registry lists 264 enrolled. Improved progression-free survival in this report did not demonstrate improved overall survival. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00353496); PubMed PMID 25014687 (https://pubmed.ncbi.nlm.nih.gov/25014687/)2026-09-20Study context addedlanreotidehttps://peptidescanner.com/studies/#study-nct00672074peptidescanner:whats-new:study:NCT00672074:v1Recovery of gastrointestinal function, assessed daily until hospital discharge. Site addition: 2026-09-20. Source date: Registry source date 2017-04-14. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report describes 117 enrolled and 114 in safety and modified intention-to-treat analyses. The primary efficacy difference was not statistically significant; this route and setting do not establish effects for other proposed uses. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00672074); PubMed PMID 25331030 (https://pubmed.ncbi.nlm.nih.gov/25331030/)2026-09-20Study context addedipamorelinhttps://peptidescanner.com/studies/#study-nct00690898peptidescanner:whats-new:study:NCT00690898:v1The proportion with a relevant reduction in pituitary tumor volume on MRI at week 48. Site addition: 2026-09-20. Source date: Registry source date 2022-10-14. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report describes 90 entrants and 89 in the primary analysis; the registry lists 108 enrolled. These are source-specific counts, not an interchangeable analyzed population. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00690898); PubMed PMID 24423301 (https://pubmed.ncbi.nlm.nih.gov/24423301/)2026-09-20Study context addedlanreotidehttps://peptidescanner.com/studies/#study-nct00730015peptidescanner:whats-new:study:NCT00730015:v1The proportion with at least three complete spontaneous bowel movements per week and at least one more than baseline, for at least nine of twelve weeks. Site addition: 2026-09-20. Source date: Registry source date 2013-01-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry identifies protocol MCP-103-303 and 643 enrolled participants. Only Trial 303 outcomes from the two-trial paper are shown here; the paper’s total of 1,276 covers both trials. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00730015); PubMed PMID 21830967 (https://pubmed.ncbi.nlm.nih.gov/21830967/)2026-09-20Study context addedlinaclotidehttps://peptidescanner.com/studies/#study-nct00765882peptidescanner:whats-new:study:NCT00765882:v1The proportion with at least three complete spontaneous bowel movements per week and at least one more than baseline, for at least nine of twelve weeks. Site addition: 2026-09-20. Source date: Registry source date 2013-01-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry identifies protocol LIN-MD-01 and 633 enrolled participants. Only Trial 01 outcomes from the two-trial paper are shown here; combined safety reporting should not be assigned to either trial alone. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00765882); PubMed PMID 21830967 (https://pubmed.ncbi.nlm.nih.gov/21830967/)2026-09-20Study context addedlinaclotidehttps://peptidescanner.com/studies/#study-nct00842348peptidescanner:whats-new:study:NCT00842348:v1Adverse events throughout the extension; the registry identifies safety as the primary outcome. Site addition: 2026-09-20. Source date: Registry source date 2022-10-12. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The reported 38.5-month progression-free survival starts at core-trial randomization, not extension entry. Extension entrants were selected and all received active treatment, so this is not a new randomized long-term comparison. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00842348); PubMed PMID 33052555 (https://pubmed.ncbi.nlm.nih.gov/33052555/)2026-09-20Study context addedlanreotidehttps://peptidescanner.com/studies/#study-nct00979745peptidescanner:whats-new:study:NCT00979745:v1Direct sunlight exposure without phototoxicity-related pain between 10:00 and 15:00, from baseline through day 270. Site addition: 2026-09-20. Source date: Registry source date 2021-10-12. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This European protocol used a different daily sunlight window and follow-up period from the US trial in the same paper. The exposure-hour totals are not directly comparable across studies. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT00979745); PubMed PMID 26132941 (https://pubmed.ncbi.nlm.nih.gov/26132941/)2026-09-20Study context addedafamelanotidehttps://peptidescanner.com/studies/#study-nct01144338peptidescanner:whats-new:study:NCT01144338:v1Time to the first major cardiovascular event, tested for both safety noninferiority and efficacy superiority. Site addition: 2026-09-20. Source date: Registry source date 2018-08-08. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The safety noninferiority criterion was met, but the superiority criterion for reducing cardiovascular events was not. Those are different questions. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01144338); PubMed PMID 28910237 (https://pubmed.ncbi.nlm.nih.gov/28910237/)2026-09-20Study context addedexenatidehttps://peptidescanner.com/studies/#study-nct01147250peptidescanner:whats-new:study:NCT01147250:v1Time to cardiovascular death, nonfatal heart attack, nonfatal stroke or hospitalization for unstable angina. Site addition: 2026-09-20. Source date: Registry source date 2016-12-20. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The trial met its noninferiority criterion but did not show superiority. Its cardiovascular composite includes unstable-angina hospitalization, unlike some other trials in this collection. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01147250); PubMed PMID 26630143 (https://pubmed.ncbi.nlm.nih.gov/26630143/)2026-09-20Study context addedlixisenatidehttps://peptidescanner.com/studies/#study-nct01179048peptidescanner:whats-new:study:NCT01179048:v1Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke. Site addition: 2026-09-20. Source date: Registry source date 2019-07-17. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The reported median follow-up was 3.8 years. The study population had type 2 diabetes and high cardiovascular risk; it does not establish the same result in lower-risk populations. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01179048); PubMed PMID 27295427 (https://pubmed.ncbi.nlm.nih.gov/27295427/)2026-09-20Study context addedliraglutidehttps://peptidescanner.com/studies/#study-nct01263717peptidescanner:whats-new:study:NCT01263717:v1Change in visceral adipose tissue and liver fat at six months. Site addition: 2026-09-20. Source date: Registry source date 2017-10-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry lists 54 enrolled; the paper describes 50 randomized and 48 treated. This small, single-center study measured fat changes rather than long-term clinical outcomes. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01263717); PubMed PMID 25038357 (https://pubmed.ncbi.nlm.nih.gov/25038357/)2026-09-20Study context addedtesamorelinhttps://peptidescanner.com/studies/#study-nct01272219peptidescanner:whats-new:study:NCT01272219:v1Weight change and the proportions losing at least 5% or more than 10% of baseline weight at week 56; the registry also includes a later diabetes-onset endpoint. Site addition: 2026-09-20. Source date: Registry source date 2018-01-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This paper reports the 56-week comparison. The registered 160-week diabetes-onset endpoint belongs to a longer follow-up question and should not be inferred from this report. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01272219); PubMed PMID 26132939 (https://pubmed.ncbi.nlm.nih.gov/26132939/)2026-09-20Study context addedliraglutidehttps://peptidescanner.com/studies/#study-nct01382719peptidescanner:whats-new:study:NCT01382719:v1Change in the number of satisfying sexual events per month during 12 weeks of randomized treatment. Site addition: 2026-09-20. Source date: Registry source date 2014-12-18. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry lists 612 enrolled while the report describes 327 in its efficacy population. The positive result pools selected treatment groups; this phase 2 endpoint should not be substituted for the endpoints of later trials. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01382719); PubMed PMID 27181790 (https://pubmed.ncbi.nlm.nih.gov/27181790/)2026-09-20Study context addedbremelanotidehttps://peptidescanner.com/studies/nct01394952/versions/1/peptidescanner:whats-new:study:NCT01394952:v1Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke. Site addition: 2026-09-20. Source date: Registry source date 2019-10-08. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The reported median follow-up was 5.4 years. The composite result does not establish benefit for every component, and all-cause mortality did not differ significantly. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01394952); PubMed PMID 31189511 (https://pubmed.ncbi.nlm.nih.gov/31189511/)2026-09-20Study context addeddulaglutidehttps://peptidescanner.com/studies/#study-nct01430195peptidescanner:whats-new:study:NCT01430195:v1Changes in pigmentation assessed with VASI and VETF measures across specified body regions over six months. Site addition: 2026-09-20. Source date: Registry source date 2013-03-22. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report describes 55 randomized participants with skin phototypes III to VI; the registry lists 56 enrolled. This combination comparison does not isolate the effect of afamelanotide used alone. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01430195); PubMed PMID 25230094 (https://pubmed.ncbi.nlm.nih.gov/25230094/)2026-09-20Study context addedafamelanotidehttps://peptidescanner.com/studies/#study-nct01605136peptidescanner:whats-new:study:NCT01605136:v1Direct sunlight exposure without pain between 10:00 and 18:00, recorded daily for six months. Site addition: 2026-09-20. Source date: Registry source date 2019-09-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry reports 93 enrolled participants while the abstract reports 94. That discrepancy remains explicit. The US and European protocols used different daily sunlight windows and follow-up periods. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01605136); PubMed PMID 26132941 (https://pubmed.ncbi.nlm.nih.gov/26132941/)2026-09-20Study context addedafamelanotidehttps://peptidescanner.com/studies/#study-nct01621178peptidescanner:whats-new:study:NCT01621178:v1Change in HbA1c at week 26. Site addition: 2026-09-20. Source date: Registry source date 2019-09-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The study continued for 52 weeks, but the primary comparison was glycemic control at week 26. Kidney measurements were secondary outcomes. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01621178); PubMed PMID 29910024 (https://pubmed.ncbi.nlm.nih.gov/29910024/)2026-09-20Study context addeddulaglutidehttps://peptidescanner.com/studies/#study-nct01657162peptidescanner:whats-new:study:NCT01657162:v1New vertebral fractures measured from the parent-study baseline through the first six extension months. Site addition: 2026-09-20. Source date: Registry source date 2020-12-11. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry primary window ends at cumulative month 25; this later report follows the treatment sequence through month 43. Both extension groups received alendronate. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01657162); PubMed PMID 29800372 (https://pubmed.ncbi.nlm.nih.gov/29800372/)2026-09-20Study context addedabaloparatidehttps://peptidescanner.com/studies/#study-nct01982240peptidescanner:whats-new:study:NCT01982240:v1A sustained complete spontaneous bowel-movement response over 12 treatment weeks. Site addition: 2026-09-20. Source date: Registry source date 2019-12-26. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry distinguishes 1,394 randomizations from 1,346 unique patients in the intention-to-treat population, after excluding repeat enrollments. The abstract’s randomized count is not the efficacy-analysis denominator. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT01982240); PubMed PMID 28169285 (https://pubmed.ncbi.nlm.nih.gov/28169285/)2026-09-20Study context addedplecanatidehttps://peptidescanner.com/studies/#study-nct02122471peptidescanner:whats-new:study:NCT02122471:v1A sustained complete spontaneous bowel-movement response over 12 treatment weeks. Site addition: 2026-09-20. Source date: Registry source date 2019-05-28. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry reports 1,410 randomizations and an intention-to-treat population of 1,337 after excluding repeat enrollments. The closer-reading notes explain which populations support efficacy and safety results. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02122471); PubMed PMID 29147135 (https://pubmed.ncbi.nlm.nih.gov/29147135/)2026-09-20Study context addedplecanatidehttps://peptidescanner.com/studies/#study-nct02171130peptidescanner:whats-new:study:NCT02171130:v1The proportion of participants awakening or returning to their normal status within 30 minutes, assessed by their caregivers. Site addition: 2026-09-20. Source date: Registry source date 2019-10-15. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This uncontrolled study uses both patient-level and event-level outcomes. The efficacy analysis excluded events requiring other treatment before a response; its response percentage is not an all-treated success rate. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02171130); PubMed PMID 29504662 (https://pubmed.ncbi.nlm.nih.gov/29504662/)2026-09-20Study context addedglucagonhttps://peptidescanner.com/studies/#study-nct02333071peptidescanner:whats-new:study:NCT02333071:v1Changes in the Female Sexual Function Index desire score and the Female Sexual Distress Scale item concerning distress about low desire; the registry includes the core study and extension observation periods. Site addition: 2026-09-20. Source date: Registry source date 2021-04-09. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The selected report concerns the 24-week blinded core study. It reports improvement in both primary scales; the prespecified secondary count of satisfying sexual events did not differ significantly. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02333071); PubMed PMID 31599840 (https://pubmed.ncbi.nlm.nih.gov/31599840/)2026-09-20Study context addedbremelanotidehttps://peptidescanner.com/studies/#study-nct02338960peptidescanner:whats-new:study:NCT02338960:v1Changes in the Female Sexual Function Index desire score and the Female Sexual Distress Scale item concerning distress about low desire; the registry includes the core study and extension observation periods. Site addition: 2026-09-20. Source date: Registry source date 2021-01-28. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The selected report concerns the 24-week blinded core study. It reports improvement in both primary scales; the prespecified secondary count of satisfying sexual events did not differ significantly. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02338960); PubMed PMID 31599840 (https://pubmed.ncbi.nlm.nih.gov/31599840/)2026-09-20Study context addedbremelanotidehttps://peptidescanner.com/studies/#study-nct02896192peptidescanner:whats-new:study:NCT02896192:v1The proportion of the pivotal cohort reaching at least 10% weight loss after approximately one year. Site addition: 2026-09-20. Source date: Registry source date 2023-09-21. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry’s total enrollment is 15; the selected paper reports the ten-person pivotal POMC cohort. The primary one-year result is not a parallel placebo comparison, and the hunger analysis selects initial responders. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02896192); PubMed PMID 33137293 (https://pubmed.ncbi.nlm.nih.gov/33137293/)2026-09-20Study context addedsetmelanotidehttps://peptidescanner.com/studies/#study-nct02963766peptidescanner:whats-new:study:NCT02963766:v1Change in HbA1c at week 26, pooling the dulaglutide groups. Site addition: 2026-09-20. Source date: Registry source date 2022-07-01. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The placebo-controlled comparison lasted 26 weeks; participants originally receiving placebo then received dulaglutide. The later extension is not another concurrent placebo comparison. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT02963766); PubMed PMID 35658022 (https://pubmed.ncbi.nlm.nih.gov/35658022/)2026-09-20Study context addeddulaglutidehttps://peptidescanner.com/studies/#study-nct03085095peptidescanner:whats-new:study:NCT03085095:v1Sustained testosterone suppression from day 29 through day 337. Site addition: 2026-09-20. Source date: Registry source date 2022-01-18. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The paper describes 930 treated participants, while the registry lists 1,134 enrolled across the registered study. The primary endpoint concerns testosterone suppression rather than cancer survival. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03085095); PubMed PMID 32469183 (https://pubmed.ncbi.nlm.nih.gov/32469183/)2026-09-20Study context addedleuprolidehttps://peptidescanner.com/studies/#study-nct03098797peptidescanner:whats-new:study:NCT03098797:v1Six-minute walking distance and total fatigue score during the controlled 12-week treatment periods. Site addition: 2026-09-20. Source date: Registry source date 2024-04-16. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The controlled phase did not meet either primary endpoint. Later open-label improvements come from a smaller group without a concurrent placebo comparison. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03098797); PubMed PMID 33077895 (https://pubmed.ncbi.nlm.nih.gov/33077895/)2026-09-20Study context addedelamipretidehttps://peptidescanner.com/studies/#study-nct03287960peptidescanner:whats-new:study:NCT03287960:v1The proportion of the pivotal cohort reaching at least 10% weight loss after approximately one year. Site addition: 2026-09-20. Source date: Registry source date 2023-05-23. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry’s total enrollment is 15; the selected paper reports the eleven-person pivotal LEPR cohort. The primary one-year result is not a parallel placebo comparison, and the hunger analysis selects initial responders. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03287960); PubMed PMID 33137293 (https://pubmed.ncbi.nlm.nih.gov/33137293/)2026-09-20Study context addedsetmelanotidehttps://peptidescanner.com/studies/nct03323749/versions/1/peptidescanner:whats-new:study:NCT03323749:v1Change in six-minute walking distance and symptom-assessment total fatigue score at week 24. Site addition: 2026-09-20. Source date: Registry source date 2022-01-24. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: Neither primary endpoint was met. Findings in primary mitochondrial myopathy should not be substituted for evidence in Barth syndrome. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03323749); PubMed PMID 37268435 (https://pubmed.ncbi.nlm.nih.gov/37268435/)2026-09-20Study context addedelamipretidehttps://peptidescanner.com/studies/#study-nct03339453peptidescanner:whats-new:study:NCT03339453:v1The proportion meeting the prespecified glucose-recovery criterion within 30 minutes after administration, without additional intervention. Site addition: 2026-09-20. Source date: Registry source date 2019-09-23. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This was a crossover comparison under controlled clinical conditions. Its primary efficacy analysis and safety population differ, and it did not test caregiver performance in an emergency. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03339453); PubMed PMID 32514794 (https://pubmed.ncbi.nlm.nih.gov/32514794/)2026-09-20Study context addedglucagonhttps://peptidescanner.com/studies/#study-nct03439943peptidescanner:whats-new:study:NCT03439943:v1Change in the MDS-UPDRS part III motor score at month 12. Site addition: 2026-09-20. Source date: Registry source date 2025-11-28. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The primary assessment was performed while participants were taking their Parkinson medication. The two-month washout assessment is a different time point and does not establish durable disease modification. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03439943); PubMed PMID 38598572 (https://pubmed.ncbi.nlm.nih.gov/38598572/)2026-09-20Study context addedlixisenatidehttps://peptidescanner.com/studies/#study-nct03512262peptidescanner:whats-new:study:NCT03512262:v1Percentage change in lumbar-spine bone mineral density at month 12. Site addition: 2026-09-20. Source date: Registry source date 2023-04-07. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The primary outcome was bone density. The selected report does not establish a reduction in fractures in this population. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03512262); PubMed PMID 36190391 (https://pubmed.ncbi.nlm.nih.gov/36190391/)2026-09-20Study context addedabaloparatidehttps://peptidescanner.com/studies/nct03548935/versions/1/peptidescanner:whats-new:study:NCT03548935:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 68. Site addition: 2026-09-20. Source date: Registry source date 2021-11-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The study had two primary weight endpoints. Its results do not describe what happens after treatment is stopped. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03548935); PubMed PMID 33567185 (https://pubmed.ncbi.nlm.nih.gov/33567185/)2026-09-20Study context addedsemaglutidehttps://peptidescanner.com/studies/nct03574597/versions/1/peptidescanner:whats-new:study:NCT03574597:v1Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke; the registry observation window extended to 240 weeks. Site addition: 2026-09-20. Source date: Registry source date 2024-08-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report gives a mean follow-up of 39.8 months. That observed follow-up differs from the maximum registry observation window. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03574597); PubMed PMID 37952131 (https://pubmed.ncbi.nlm.nih.gov/37952131/)2026-09-20Study context addedsemaglutidehttps://peptidescanner.com/studies/#study-nct03856047peptidescanner:whats-new:study:NCT03856047:v1Percentage change in body weight at week 26. Site addition: 2026-09-20. Source date: Registry source date 2024-07-05. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The trial included 706 randomized participants in total. The active groups were not masked from one another; the masking concerned active treatment versus placebo. The report distinguishes trial-product and treatment-policy analyses. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT03856047); PubMed PMID 34798060 (https://pubmed.ncbi.nlm.nih.gov/34798060/)2026-09-20Study context addedcagrilintideliraglutidehttps://peptidescanner.com/studies/nct04026113/versions/1/peptidescanner:whats-new:study:NCT04026113:v1For functional constipation, change in weekly spontaneous bowel-movement frequency over 12 weeks; the registry has a separate primary endpoint for its IBS-C cohort. Site addition: 2026-09-20. Source date: Registry source date 2024-11-26. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry covers 438 participants across two conditions. This report concerns 330 randomized children with functional constipation, of whom 328 received treatment. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04026113); PubMed PMID 38211604 (https://pubmed.ncbi.nlm.nih.gov/38211604/)2026-09-20Study context addedlinaclotidehttps://peptidescanner.com/studies/#study-nct04163874peptidescanner:whats-new:study:NCT04163874:v1Two primary comparisons over 12-day assessment periods: time with glucose in the target range and the Emotional Burden score from the Diabetes Distress Scale. Site addition: 2026-09-20. Source date: Registry source date 2022-10-10. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The comparison changes both the drug combination and the meal-announcement approach. The publication describes 32 enrolled and 30 completing analysis; the registry lists 36 enrolled. Glucose noninferiority does not establish reduced emotional burden. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04163874); PubMed PMID 38906614 (https://pubmed.ncbi.nlm.nih.gov/38906614/)2026-09-20Study context addedpramlintidehttps://peptidescanner.com/studies/nct04184622/versions/1/peptidescanner:whats-new:study:NCT04184622:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 72. Site addition: 2026-09-20. Source date: Registry source date 2025-07-24. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The selected report concerns the 72-week weight endpoints. Later follow-up reports require their own appraisal. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04184622); PubMed PMID 35658024 (https://pubmed.ncbi.nlm.nih.gov/35658024/)2026-09-20Study context addedtirzepatidehttps://peptidescanner.com/studies/#study-nct04478708peptidescanner:whats-new:study:NCT04478708:v1The number of participants with treatment-emergent adverse events, with observation windows varying by study part. Site addition: 2026-09-20. Source date: Registry source date 2025-12-10. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The paper contains both animal experiments and human observations. Only the human study belongs to this trial card; weight change was not the registered primary safety endpoint. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04478708); PubMed PMID 38316982 (https://pubmed.ncbi.nlm.nih.gov/38316982/)2026-09-20Study context addedmaridebart-cafraglutidehttps://peptidescanner.com/studies/#study-nct04771273peptidescanner:whats-new:study:NCT04771273:v1Improvement in liver histology after 48 weeks, with analyses by planned and actual maintenance treatment. Site addition: 2026-09-20. Source date: Registry source date 2024-12-03. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The reported primary result was improvement in steatohepatitis without worsening fibrosis. Improvement in fibrosis itself was a separate secondary outcome. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04771273); PubMed PMID 38847460 (https://pubmed.ncbi.nlm.nih.gov/38847460/)2026-09-20Study context addedsurvodutidehttps://peptidescanner.com/studies/#study-nct04867785peptidescanner:whats-new:study:NCT04867785:v1Change in HbA1c at week 24. Site addition: 2026-09-20. Source date: Registry source date 2023-07-03. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The report distinguishes 281 randomized participants from 275 included in efficacy analyses. Weight change at week 36 was a secondary endpoint. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04867785); PubMed PMID 37385280 (https://pubmed.ncbi.nlm.nih.gov/37385280/)2026-09-20Study context addedretatrutidehttps://peptidescanner.com/studies/nct04881760/versions/1/peptidescanner:whats-new:study:NCT04881760:v1Percentage change in body weight at week 24. Site addition: 2026-09-20. Source date: Registry source date 2023-09-13. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The often-cited 48-week weight results are secondary outcomes; the primary endpoint was measured at week 24. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04881760); PubMed PMID 37366315 (https://pubmed.ncbi.nlm.nih.gov/37366315/)2026-09-20Study context addedretatrutidehttps://peptidescanner.com/studies/#study-nct04962503peptidescanner:whats-new:study:NCT04962503:v1Change in infarct volume from day 0 to days 3 and 9. Site addition: 2026-09-20. Source date: Registry source date 2023-04-11. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry lists imaging as the primary outcome; the article emphasizes feasibility and safety. Six uncontrolled observations cannot establish treatment efficacy or safety. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT04962503); PubMed PMID 37496004 (https://pubmed.ncbi.nlm.nih.gov/37496004/)2026-09-20Study context addedafamelanotidehttps://peptidescanner.com/studies/#study-nct05292911peptidescanner:whats-new:study:NCT05292911:v1The number of participants with treatment-emergent adverse events through day 110. Site addition: 2026-09-20. Source date: Registry source date 2023-07-27. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry primary outcome concerns adverse events; the publication calls liver-fat change its primary efficacy outcome. This is an extension cohort, and MRI liver fat is not a biopsy-based fibrosis outcome. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05292911); PubMed PMID 41113119 (https://pubmed.ncbi.nlm.nih.gov/41113119/)2026-09-20Study context addedpemvidutidehttps://peptidescanner.com/studies/#study-nct05369390peptidescanner:whats-new:study:NCT05369390:v1The number of treatment-emergent adverse events, with follow-up windows of 22, 31 or 105 days depending on study part. Site addition: 2026-09-20. Source date: Registry source date 2025-06-15. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The 144 participants were spread across different study parts. Weight-related outcomes were exploratory, and the parts did not all share the same treatment duration. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05369390); PubMed PMID 40550229 (https://pubmed.ncbi.nlm.nih.gov/40550229/)2026-09-20Study context addedamycretinhttps://peptidescanner.com/studies/#study-nct05394519peptidescanner:whats-new:study:NCT05394519:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 68. Site addition: 2026-09-20. Source date: Registry source date 2026-01-28. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: These are combination-treatment results. The paper identifies a treatment-policy analysis; its estimates should not be mixed with a different estimand without checking the analysis definition. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05394519); PubMed PMID 40544432 (https://pubmed.ncbi.nlm.nih.gov/40544432/)2026-09-20Study context addedcagrilintidesemaglutidehttps://peptidescanner.com/studies/#study-nct05567796peptidescanner:whats-new:study:NCT05567796:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 68, comparing the combination with placebo. Site addition: 2026-09-20. Source date: Registry source date 2026-08-31. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The registry still lists estimated enrollment of 3,400; the report describes 3,417 randomized participants. Its headline combination-versus-placebo result is not a cagrilintide-alone result. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05567796); PubMed PMID 40544433 (https://pubmed.ncbi.nlm.nih.gov/40544433/)2026-09-20Study context addedcagrilintidesemaglutidehttps://peptidescanner.com/studies/#study-nct05606913peptidescanner:whats-new:study:NCT05606913:v1Change in HbA1c from baseline to week 28. Site addition: 2026-09-20. Source date: Registry source date 2024-08-23. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This active-comparator trial concerns selected treatment groups in a specified diabetes population. It does not rank the drugs across other conditions, treatment settings or long-term outcomes. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05606913); PubMed PMID 41407860 (https://pubmed.ncbi.nlm.nih.gov/41407860/)2026-09-20Study context addedmazdutidedulaglutidehttps://peptidescanner.com/studies/#study-nct05607680peptidescanner:whats-new:study:NCT05607680:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 32. Site addition: 2026-09-20. Source date: Registry source date 2024-11-12. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The study continued to week 48, but the coprimary endpoints were assessed at week 32. Its population and analysis definition should accompany any quoted weight result. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05607680); PubMed PMID 40421736 (https://pubmed.ncbi.nlm.nih.gov/40421736/)2026-09-20Study context addedmazdutidehttps://peptidescanner.com/studies/#study-nct05669599peptidescanner:whats-new:study:NCT05669599:v1Percentage change in body weight at week 52. Site addition: 2026-09-20. Source date: Registry source date 2026-01-20. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The 592 randomized participants included 465 without diabetes and 127 with type 2 diabetes. These cohorts and the treatment-policy and efficacy estimates should remain separate. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05669599); PubMed PMID 40549887 (https://pubmed.ncbi.nlm.nih.gov/40549887/)2026-09-20Study context addedmaridebart-cafraglutidehttps://peptidescanner.com/studies/#study-nct05989711peptidescanner:whats-new:study:NCT05989711:v1Two histology outcomes at week 24: disease resolution without worsening fibrosis, and fibrosis improvement without worsening disease; the registry also lists adverse events through week 52. Site addition: 2026-09-20. Source date: Registry source date 2026-05-18. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The selected publication reports the 24-week analysis. One histology endpoint was met and the other was not; this should not be summarized as demonstrated fibrosis benefit. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT05989711); PubMed PMID 41237796 (https://pubmed.ncbi.nlm.nih.gov/41237796/)2026-09-20Study context addedpemvidutidehttps://peptidescanner.com/studies/#study-nct06064006peptidescanner:whats-new:study:NCT06064006:v1The number of treatment-emergent adverse events, assessed through the end of each study part. Site addition: 2026-09-20. Source date: Registry source date 2025-11-19. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: Weight findings came from small cohorts followed for different lengths of time. The authors reported substantial withdrawal, which limits interpretation of the estimates. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06064006); PubMed PMID 40550231 (https://pubmed.ncbi.nlm.nih.gov/40550231/)2026-09-20Study context addedamycretinhttps://peptidescanner.com/studies/#study-nct06066515peptidescanner:whats-new:study:NCT06066515:v1Percentage weight change and the proportion losing at least 5% of baseline weight at week 76. Site addition: 2026-09-20. Source date: Registry source date 2026-03-12. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The paper describes 725 participants and the registry lists 726 enrolled. Its treatment-regimen estimates include treatment discontinuation and other specified intercurrent events; they should not be mixed with efficacy estimates from a different analysis. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06066515); PubMed PMID 42253238 (https://pubmed.ncbi.nlm.nih.gov/42253238/)2026-09-20Study context addedsurvodutidehttps://peptidescanner.com/studies/#study-nct06124807peptidescanner:whats-new:study:NCT06124807:v1Percentage change in body weight at week 32. Site addition: 2026-09-20. Source date: Registry source date 2026-04-21. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The trial continued to week 48, but its primary weight endpoint was at week 32. Its hypothetical efficacy estimand and US population should remain distinct from the GLORY-1 report. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06124807); PubMed PMID 42628555 (https://pubmed.ncbi.nlm.nih.gov/42628555/)2026-09-20Study context addedmazdutidehttps://peptidescanner.com/studies/#study-nct06323161peptidescanner:whats-new:study:NCT06323161:v1Change in HbA1c at week 40. Site addition: 2026-09-20. Source date: Registry source date 2026-09-09. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This report uses an efficacy estimand and a population already receiving basal insulin. Its estimates answer a different question from the REDEFINE weight-management trials. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06323161); PubMed PMID 42251856 (https://pubmed.ncbi.nlm.nih.gov/42251856/)2026-09-20Study context addedcagrilintidesemaglutidehttps://peptidescanner.com/studies/#study-nct06323174peptidescanner:whats-new:study:NCT06323174:v1Change in HbA1c at week 40. Site addition: 2026-09-20. Source date: Registry source date 2026-04-02. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The primary outcome concerns blood glucose; weight change was secondary. These efficacy-estimand results should not be ranked directly against treatment-policy estimates from other populations. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06323174); PubMed PMID 42251860 (https://pubmed.ncbi.nlm.nih.gov/42251860/)2026-09-20Study context addedcagrilintidesemaglutidehttps://peptidescanner.com/studies/#study-nct06354660peptidescanner:whats-new:study:NCT06354660:v1Change in HbA1c from baseline to week 40. Site addition: 2026-09-20. Source date: Registry source date 2026-03-05. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The trial randomized 537 of 930 screened participants. Weight change was secondary to the primary glycemic endpoint; this 40-week study does not establish long-term cardiovascular outcomes. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06354660); PubMed PMID 42250575 (https://pubmed.ncbi.nlm.nih.gov/42250575/)2026-09-20Study context addedretatrutidehttps://peptidescanner.com/studies/#study-nct06542874peptidescanner:whats-new:study:NCT06542874:v1Change in HbA1c from baseline to week 36. Site addition: 2026-09-20. Source date: Registry source date 2026-08-13. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: Both reports share NCT06542874: 186 participants in the oral cohort and 262 in the subcutaneous cohort. They are two route reports within one registered study, not independent trial replications. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06542874); PubMed PMID 42532079 (https://pubmed.ncbi.nlm.nih.gov/42532079/); PubMed PMID 42532080 (https://pubmed.ncbi.nlm.nih.gov/42532080/)2026-09-20Study context addedamycretinhttps://peptidescanner.com/studies/#study-nct06559527peptidescanner:whats-new:study:NCT06559527:v1Total drug exposure, measured as area under the concentration-time curve from time zero to infinity, using samples collected through day 28. Site addition: 2026-09-20. Source date: Registry source date 2025-03-30. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The 42 participants were divided among five renal-function groups. This short pharmacokinetic study does not establish treatment benefit, long-term safety or a dosing recommendation. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06559527); PubMed PMID 42443140 (https://pubmed.ncbi.nlm.nih.gov/42443140/)2026-09-20Study context addedamycretinhttps://peptidescanner.com/studies/#study-nct06662539peptidescanner:whats-new:study:NCT06662539:v1Percentage change in body weight at week 28. Site addition: 2026-09-20. Source date: Registry source date 2026-03-23. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: The retrieved registry marks the study completed and enrollment as actual, but contains no posted results. A completed registry status alone does not supply an effect estimate. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06662539)2026-09-20Study context addedpetrelintidehttps://peptidescanner.com/studies/#study-nct06926842peptidescanner:whats-new:study:NCT06926842:v1Percentage change in body weight at week 28. Site addition: 2026-09-20. Source date: Registry source date 2026-09-09. Review date: 2026-09-20. Source checked: 2026-09-20. Limits: This registered population has type 2 diabetes. The retrieved record contains no posted results; this card does not substitute for a published results appraisal. Registry information is sponsor-submitted; a registry check does not refresh the article appraisal or establish a treatment recommendation. Sources: ClinicalTrials.gov registry (https://clinicaltrials.gov/study/NCT06926842)2026-09-20Study context addedpetrelintidehttps://peptidescanner.com/peptides/cagrilintide/#supervised-synthesispeptidescanner:whats-new:review:cagrilintide:v3The selected cagrilintide-alone study reported weight reduction. Later combination trials reported weight or glycemic improvements, but their results cannot be attributed to cagrilintide alone. Gastrointestinal adverse events were common, and a correction to REIMAGINE 2 remains to be reconciled. Source-integrity notice: Erratum reported in publisher metadata for PMID 42251859 on 2026-06-19, 2026-08-01. Notice: https://doi.org/10.1016/s2213-8587(26)00157-9. Cited source: https://pubmed.ncbi.nlm.nih.gov/42251859/. Crossref metadata identifies the notice but does not by itself explain what wording changed. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: Do larger and longer trials confirm durability, characterize uncommon harms, and show outcomes after treatment stops? Sources: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (https://pubmed.ncbi.nlm.nih.gov/34798060/); Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. (https://pubmed.ncbi.nlm.nih.gov/40544432/); Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. (https://pubmed.ncbi.nlm.nih.gov/40544433/); Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (https://pubmed.ncbi.nlm.nih.gov/42251856/); Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. (https://pubmed.ncbi.nlm.nih.gov/42251859/); Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. (https://pubmed.ncbi.nlm.nih.gov/42251860/)2026-09-20Human Evidence Review updatedcagrilintidehttps://peptidescanner.com/peptides/afamelanotide/#supervised-synthesispeptidescanner:whats-new:review:afamelanotide:v2The EPP trials reported longer pain-free sunlight exposure. Evidence in vitiligo concerns combination treatment with phototherapy; the six-person stroke study cannot establish treatment benefit or safety. Results from these different settings should not be pooled. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: How durable are benefits and harms in broader EPP populations, including those underrepresented in the trials? Sources: Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. (https://pubmed.ncbi.nlm.nih.gov/25230094/); Afamelanotide for Erythropoietic Protoporphyria. (https://pubmed.ncbi.nlm.nih.gov/26132941/); A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. (https://pubmed.ncbi.nlm.nih.gov/37496004/); German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP). (https://pubmed.ncbi.nlm.nih.gov/40082741/)2026-09-20Human Evidence Review updatedafamelanotidehttps://peptidescanner.com/peptides/bremelanotide/#supervised-synthesispeptidescanner:whats-new:review:bremelanotide:v2RECONNECT reported improvements in desire and related distress in premenopausal women with hypoactive sexual desire disorder. Nausea, flushing and headache were more frequent with bremelanotide. Safety analyses overlap the efficacy-trial population. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: How do the magnitude of symptom changes, treatment discontinuation and patient preferences affect interpretation? Sources: Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. (https://pubmed.ncbi.nlm.nih.gov/27181790/); Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. (https://pubmed.ncbi.nlm.nih.gov/31599840/); Safety Profile of Bremelanotide Across the Clinical Development Program. (https://pubmed.ncbi.nlm.nih.gov/35147466/)2026-09-20Human Evidence Review updatedbremelanotidehttps://peptidescanner.com/peptides/glucagon/#supervised-synthesispeptidescanner:whats-new:review:glucagon:v2Controlled studies found high recovery rates after experimentally induced hypoglycemia. A small uncontrolled study also reported recovery during spontaneous episodes. Laboratory recovery times and trained-caregiver observations do not establish equivalent performance in every emergency. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: How do current product labels distinguish rescue and diagnostic uses and age-specific indications? Sources: Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. (https://pubmed.ncbi.nlm.nih.gov/29504662/); Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. (https://pubmed.ncbi.nlm.nih.gov/32514794/); Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. (https://pubmed.ncbi.nlm.nih.gov/34620618/)2026-09-20Human Evidence Review updatedglucagonhttps://peptidescanner.com/peptides/leuprolide/#supervised-synthesispeptidescanner:whats-new:review:leuprolide:v2In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: How do the compared approaches affect long-term patient-important outcomes, harms, and treatment persistence beyond the reviewed follow-up windows? Sources: Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain (https://pubmed.ncbi.nlm.nih.gov/21300339/); Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (https://pubmed.ncbi.nlm.nih.gov/32469183/)2026-09-20Human Evidence Review updatedleuprolidehttps://peptidescanner.com/peptides/linaclotide/#supervised-synthesispeptidescanner:whats-new:review:linaclotide:v2Randomized trials reported improved bowel-movement measures over 12 weeks. Diarrhea is an important adverse effect; the pediatric trial included a serious dehydration event related to severe diarrhea. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: What additional trials address irritable bowel syndrome and other age groups? Sources: Two randomized trials of linaclotide for chronic constipation. (https://pubmed.ncbi.nlm.nih.gov/21830967/); Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (https://pubmed.ncbi.nlm.nih.gov/38211604/)2026-09-20Human Evidence Review updatedlinaclotidehttps://peptidescanner.com/peptides/plecanatide/#supervised-synthesispeptidescanner:whats-new:review:plecanatide:v2The trials found more participants met prespecified bowel-response endpoints with plecanatide than placebo. Diarrhea occurred more often with active treatment; these 12-week studies do not establish comparative superiority to other medicines. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: What do current labels establish about pediatric restrictions and serious diarrhea? Sources: A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. (https://pubmed.ncbi.nlm.nih.gov/28169285/); Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. (https://pubmed.ncbi.nlm.nih.gov/29147135/); Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. (https://pubmed.ncbi.nlm.nih.gov/29545635/)2026-09-20Human Evidence Review updatedplecanatidehttps://peptidescanner.com/peptides/setmelanotide/#supervised-synthesispeptidescanner:whats-new:review:setmelanotide:v2The reviewed studies reported substantial weight reductions in some participants with specific genetic diagnoses. The cohorts were very small, and the Bardet-Biedl and Alström trial reported inconclusive results for the Alström subgroup. Source-integrity notice: Erratum reported in publisher metadata for PMID 36356613 on 2023-02-01. Notice: https://doi.org/10.1016/s2213-8587(22)00360-6. Cited source: https://pubmed.ncbi.nlm.nih.gov/36356613/. Crossref metadata identifies the notice but does not by itself explain what wording changed. Site addition: 2026-09-20. Review date: 2026-09-20. Limits: How durable are benefits and harms across each genetic subgroup, and which baseline features predict response in these exceptionally small populations? Sources: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials (https://pubmed.ncbi.nlm.nih.gov/33137293/); Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period (https://pubmed.ncbi.nlm.nih.gov/36356613/)2026-09-20Human Evidence Review updatedsetmelanotidehttps://peptidescanner.com/peptides/bpc-157/#official-source-updatepeptidescanner:whats-new:official-source-note:bpc-157:v2Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source dates: Cited source date 2026-05-11, Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA BPC-157 briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193343/download)2026-09-19Official-source note updatedbpc-157https://peptidescanner.com/peptides/ghk-cu/#official-source-updatepeptidescanner:whats-new:official-source-note:ghk-cu:v2Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below. Site addition: 2026-09-19. Source dates: Cited source date 2026-02-27, Cited source date 2026-04-22, Cited source date 2026-05-14. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check later results and eligibility changes for NCT07437586; registration alone is not a clinical finding. Sources: Topical GHK-Cu Gel for Acute Skin Wound Healing (https://clinicaltrials.gov/study/NCT07437586); FDA bulk-substance safety concerns (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks); FDA 503A nominations list, May 14, 2026 (https://www.fda.gov/media/94155/download)2026-09-19Official-source note updatedghk-cuhttps://peptidescanner.com/peptides/retatrutide/#official-source-updatepeptidescanner:whats-new:official-source-note:retatrutide:v2Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below. Site addition: 2026-09-19. Source dates: Cited source date 2023-07-03, Cited source date 2023-09-13, Cited source date 2026-08-21, Cited source date 2026-08-24, Cited source date 2026-09-01. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile phase 2 registry estimates with primary publications and preserve time points and estimands. Sources: A Study of LY3437943 in Participants With Type 2 Diabetes (https://clinicaltrials.gov/study/NCT04867785); A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (https://clinicaltrials.gov/study/NCT04881760); TRIUMPH-1 · NCT05929066 (https://clinicaltrials.gov/study/NCT05929066); TRIUMPH-OUTCOMES · NCT06383390 (https://clinicaltrials.gov/study/NCT06383390); FDA concerns with unapproved GLP-1 drugs (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)2026-09-19Official-source note updatedretatrutidehttps://peptidescanner.com/peptides/abaloparatide/#official-source-updatepeptidescanner:whats-new:official-source-note:abaloparatide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2020-12-11, Cited source date 2023-04-07. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile ATOM missing-data methods and fracture outcomes with the primary report and regulatory supplement. Sources: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis (https://clinicaltrials.gov/study/NCT01657162); Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) (https://clinicaltrials.gov/study/NCT03512262)2026-09-19Official-source note publishedabaloparatidehttps://peptidescanner.com/peptides/afamelanotide/#official-source-updatepeptidescanner:whats-new:official-source-note:afamelanotide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2025-04-27, Cited source date 2026-07-27. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Appraise the six-person variegate-porphyria report and reconcile outcome definitions and safety details. Sources: Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) (https://clinicaltrials.gov/study/NCT05854784); Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients (https://clinicaltrials.gov/study/NCT06388642)2026-09-19Official-source note publishedafamelanotidehttps://peptidescanner.com/peptides/amycretin/#official-source-updatepeptidescanner:whats-new:official-source-note:amycretin:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2025-03-05, Cited source date 2025-11-19. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Match oral and subcutaneous publications to exact protocols and reconcile their analysis populations. Sources: A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (https://clinicaltrials.gov/study/NCT06049329); A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (https://clinicaltrials.gov/study/NCT06064006)2026-09-19Official-source note publishedamycretinhttps://peptidescanner.com/peptides/cagrilintide/#official-source-updatepeptidescanner:whats-new:official-source-note:cagrilintide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2024-07-05, Cited source date 2025-12-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Appraise later monotherapy and CagriSema reports separately, including discontinuation and safety denominators. Sources: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (https://clinicaltrials.gov/study/NCT03856047); Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes (https://clinicaltrials.gov/study/NCT04982575)2026-09-19Official-source note publishedcagrilintidehttps://peptidescanner.com/peptides/cjc-1295/#official-source-updatepeptidescanner:whats-new:official-source-note:cjc-1295:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2024-12-04. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA cjc-1295 briefing for the December 2024 advisory meeting (https://www.fda.gov/media/183819/download)2026-09-19Official-source note publishedcjc-1295https://peptidescanner.com/peptides/dulaglutide/#official-source-updatepeptidescanner:whats-new:official-source-note:dulaglutide:v1Selected sections of the November 16, 2022 FDA pediatric supplement review, separate from the original adult EMA assessment and later regulatory changes. Site addition: 2026-09-19. Source date: Cited source date 2022-11-16. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile the pooled point-estimate discrepancy against the statistical review and trial publication. Sources: FDA Trulicity pediatric supplement S-051 summary review (https://www.fda.gov/media/164320/download)2026-09-19Official-source note publisheddulaglutidehttps://peptidescanner.com/peptides/emideltide/#official-source-updatepeptidescanner:whats-new:official-source-note:emideltide:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA emideltide briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193344/download)2026-09-19Official-source note publishedemideltidehttps://peptidescanner.com/peptides/epitalon/#official-source-updatepeptidescanner:whats-new:official-source-note:epitalon:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA epitalon briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193345/download)2026-09-19Official-source note publishedepitalonhttps://peptidescanner.com/peptides/ipamorelin/#official-source-updatepeptidescanner:whats-new:official-source-note:ipamorelin:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2024-10-29. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA ipamorelin briefing for the October 2024 advisory meeting (https://www.fda.gov/media/182088/download)2026-09-19Official-source note publishedipamorelinhttps://peptidescanner.com/peptides/kpv/#official-source-updatepeptidescanner:whats-new:official-source-note:kpv:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA kpv briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193346/download)2026-09-19Official-source note publishedkpvhttps://peptidescanner.com/peptides/maridebart-cafraglutide/#official-source-updatepeptidescanner:whats-new:official-source-note:maridebart-cafraglutide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2025-12-10, Cited source date 2026-01-20. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Appraise the phase 1 and phase 2 publications, including weight outcomes absent from these registry results. Sources: Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity (https://clinicaltrials.gov/study/NCT04478708); Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus (https://clinicaltrials.gov/study/NCT05669599)2026-09-19Official-source note publishedmaridebart-cafraglutidehttps://peptidescanner.com/peptides/mazdutide/#official-source-updatepeptidescanner:whats-new:official-source-note:mazdutide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2025-11-17, Cited source date 2026-04-21. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile Chinese and international trial families and current jurisdiction-specific regulatory documents. Sources: A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (https://clinicaltrials.gov/study/NCT04904913); A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight (https://clinicaltrials.gov/study/NCT06124807)2026-09-19Official-source note publishedmazdutidehttps://peptidescanner.com/peptides/mots-c/#official-source-updatepeptidescanner:whats-new:official-source-note:mots-c:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA mots-c briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193347/download)2026-09-19Official-source note publishedmots-chttps://peptidescanner.com/peptides/pemvidutide/#official-source-updatepeptidescanner:whats-new:official-source-note:pemvidutide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2023-11-29, Cited source date 2026-05-18. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Retrieve and appraise MOMENTUM and IMPACT results with their original protocols and analysis plans. Sources: Efficacy and Safety of ALT-801 in the Treatment of Obesity (https://clinicaltrials.gov/study/NCT05295875); IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (https://clinicaltrials.gov/study/NCT05989711)2026-09-19Official-source note publishedpemvidutidehttps://peptidescanner.com/peptides/petrelintide/#official-source-updatepeptidescanner:whats-new:official-source-note:petrelintide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2026-03-23, Cited source date 2026-09-09. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Match ZUPREME publications or subsequent registry results to each protocol before adding effect estimates. Sources: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities (https://clinicaltrials.gov/study/NCT06662539); Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) (https://clinicaltrials.gov/study/NCT06926842)2026-09-19Official-source note publishedpetrelintidehttps://peptidescanner.com/peptides/semax/#official-source-updatepeptidescanner:whats-new:official-source-note:semax:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA semax briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193348/download)2026-09-19Official-source note publishedsemaxhttps://peptidescanner.com/peptides/survodutide/#official-source-updatepeptidescanner:whats-new:official-source-note:survodutide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2023-11-02, Cited source date 2024-12-03. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile primary papers and analysis plans with assigned-treatment and actual-treatment registry results. Sources: A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (https://clinicaltrials.gov/study/NCT04667377); A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) (https://clinicaltrials.gov/study/NCT04771273)2026-09-19Official-source note publishedsurvodutidehttps://peptidescanner.com/peptides/tb-500/#official-source-updatepeptidescanner:whats-new:official-source-note:tb-500:v1Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision. Site addition: 2026-09-19. Source date: Cited source date 2026-07-23. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Check subsequent advisory records and any final FDA action separately from the staff briefing. Sources: FDA tb-500 briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193349/download)2026-09-19Official-source note publishedtb-500https://peptidescanner.com/peptides/vosoritide/#official-source-updatepeptidescanner:whats-new:official-source-note:vosoritide:v1Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Site addition: 2026-09-19. Source dates: Cited source date 2024-06-13, Cited source date 2026-03-13. Review date: 2026-09-19. Source checked: 2026-09-19. Limits: Reconcile the young-child publication and regulatory extension with sentinel and randomized populations. Sources: A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia (https://clinicaltrials.gov/study/NCT03583697); An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (https://clinicaltrials.gov/study/NCT03989947)2026-09-19Official-source note publishedvosoritidehttps://peptidescanner.com/peptides/bpc-157/source-notes/versions/1/peptidescanner:whats-new:official-source-note:bpc-157:v1Selected sections of FDA’s May 11, 2026 evaluation prepared for the July advisory meeting; findings remain attributed to that dated assessment. Site addition: 2026-09-16. Source date: Cited source date 2026-05-11. Review date: 2026-09-16. Source checked: 2026-09-16. Limits: Check for a subsequent final FDA decision separately from the briefing and advisory process. Sources: FDA BPC-157 briefing for the July 2026 advisory meeting (https://www.fda.gov/media/193343/download)2026-09-16Official-source note publishedbpc-157